125 related articles for article (PubMed ID: 36344676)
21. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Bielecka-Wajdman AM; Lesiak M; Ludyga T; Sieroń A; Obuchowicz E
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1249-1256. PubMed ID: 28500556
[TBL] [Abstract][Full Text] [Related]
22. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
23. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
24. Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.
Talukdar S; Das SK; Pradhan AK; Emdad L; Shen XN; Windle JJ; Sarkar D; Fisher PB
Oncotarget; 2016 Aug; 7(34):54102-54119. PubMed ID: 27472461
[TBL] [Abstract][Full Text] [Related]
25. Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.
Wu HB; Yang S; Weng HY; Chen Q; Zhao XL; Fu WJ; Niu Q; Ping YF; Wang JM; Zhang X; Yao XH; Bian XW
Autophagy; 2017 Sep; 13(9):1528-1542. PubMed ID: 28812437
[TBL] [Abstract][Full Text] [Related]
26. Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43
Pelaz SG; Jaraíz-Rodríguez M; Álvarez-Vázquez A; Talaverón R; García-Vicente L; Flores-Hernández R; Gómez de Cedrón M; Tabernero M; Ramírez de Molina A; Lillo C; Medina JM; Tabernero A
EBioMedicine; 2020 Dec; 62():103134. PubMed ID: 33254027
[TBL] [Abstract][Full Text] [Related]
27. Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma.
Luwor R; Morokoff AP; Amiridis S; D'Abaco G; Paradiso L; Stylli SS; Nguyen HPT; Tarleton M; Young KA; O'Brien TJ; Robinson PJ; Chircop M; McCluskey A; Jones NC
Cancer Invest; 2019; 37(3):144-155. PubMed ID: 30907150
[TBL] [Abstract][Full Text] [Related]
28. FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells.
Torres Á; Arriagada V; Erices JI; Toro MLÁ; Rocha JD; Niechi I; Carrasco C; Oyarzún C; Quezada C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208561
[TBL] [Abstract][Full Text] [Related]
29. ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells.
Gao Z; Xu J; Fan Y; Zhang Z; Wang H; Qian M; Zhang P; Deng L; Shen J; Xue H; Zhao R; Zhou T; Guo X; Li G
J Exp Clin Cancer Res; 2022 Nov; 41(1):323. PubMed ID: 36380368
[TBL] [Abstract][Full Text] [Related]
30. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
[TBL] [Abstract][Full Text] [Related]
31. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
33. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
34. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
35. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.
Miyazaki T; Pan Y; Joshi K; Purohit D; Hu B; Demir H; Mazumder S; Okabe S; Yamori T; Viapiano M; Shin-ya K; Seimiya H; Nakano I
Clin Cancer Res; 2012 Mar; 18(5):1268-80. PubMed ID: 22230766
[TBL] [Abstract][Full Text] [Related]
36. Graphene oxide suppresses the growth and malignancy of glioblastoma stem cell-like spheroids via epigenetic mechanisms.
Wang X; Zhou W; Li X; Ren J; Ji G; Du J; Tian W; Liu Q; Hao A
J Transl Med; 2020 May; 18(1):200. PubMed ID: 32410622
[TBL] [Abstract][Full Text] [Related]
37. Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling.
Gimple RC; Kidwell RL; Kim LJY; Sun T; Gromovsky AD; Wu Q; Wolf M; Lv D; Bhargava S; Jiang L; Prager BC; Wang X; Ye Q; Zhu Z; Zhang G; Dong Z; Zhao L; Lee D; Bi J; Sloan AE; Mischel PS; Brown JM; Cang H; Huan T; Mack SC; Xie Q; Rich JN
Cancer Discov; 2019 Sep; 9(9):1248-1267. PubMed ID: 31201181
[TBL] [Abstract][Full Text] [Related]
38. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells.
Yang L; Guo H; Dong L; Wang L; Liu C; Wang X
Oncol Rep; 2014 Sep; 32(3):1303-11. PubMed ID: 24970314
[TBL] [Abstract][Full Text] [Related]
39. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner.
Gu C; Banasavadi-Siddegowda YK; Joshi K; Nakamura Y; Kurt H; Gupta S; Nakano I
Stem Cells; 2013 May; 31(5):870-81. PubMed ID: 23339114
[TBL] [Abstract][Full Text] [Related]
40. Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells.
Kuramoto K; Yamamoto M; Suzuki S; Sanomachi T; Togashi K; Seino S; Kitanaka C; Okada M
FEBS J; 2020 May; 287(10):2023-2036. PubMed ID: 31868973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
